Stockscreener 앱 받기
30.05
8.64%
2.39
시간 외 거래:
30.05
전일 마감가:
$27.66
열려 있는:
$27.7
하루 거래량:
334.45K
Relative Volume:
1.44
시가총액:
$861.73M
수익:
-
순이익/손실:
$-38.95M
주가수익비율:
-20.23
EPS:
-1.4857
순현금흐름:
$-50.43M
1주 성능:
+5.85%
1개월 성능:
+1.31%
6개월 성능:
+57.74%
1년 성능:
+0.00%
1일 변동 폭
$27.70
$30.12
1주일 범위
$27.37
$30.12
52주 변동 폭
$13.36
$33.47
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
명칭
Lb Pharmaceuticals Inc
전화
917-450-6581
주소
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
30.05 | 817.28M | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | H.C. Wainwright | Buy |
| 2026-04-10 | 개시 | Craig Hallum | Buy |
| 2026-01-09 | 개시 | Roth Capital | Buy |
| 2025-10-06 | 개시 | Leerink Partners | Outperform |
| 2025-10-06 | 개시 | Piper Sandler | Overweight |
| 2025-10-06 | 개시 | Stifel | Buy |
모두보기
Lb Pharmaceuticals Inc 주식(LBRX)의 최신 뉴스
LB Pharmaceuticals Inc (LBRX) Edges Lower Amidst Tight Trading RangeVolatility Stop - newsline.com
LBRX Q1 2026 Earnings: Narrower Loss Surpasses Estimates as Pre-Revenue Biotech Tightens SpendingFinal Results - newsline.com
LB Pharmaceuticals (NASDAQ: LBRX) supplements prospectus after CMO transition - Stock Titan
LB Pharmaceuticals Inc Announces Resignation of Anna Eramo as Chief Medical Officer, Effective June 15, 2026 - marketscreener.com
[8-K] LB PHARMACEUTICALS INC Reports Material Event - Stock Titan
[144] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
LB Pharmaceuticals Stockholders Approve Directors and Auditor - TipRanks
LB Pharmaceuticals (NASDAQ: LBRX) elects board and ratifies auditor in 2026 - Stock Titan
LB Pharmaceuticals (NASDAQ: LBRX) investors back board slate and ratify BDO as 2026 auditor - Stock Titan
LBRX Options Volatility — NASDAQ:LBRX - TradingView
LB Pharmaceuticals Inc (LBRX) Shows Modest Uptick as Stock Holds Above Key SupportPut Spread Alert - newsline.com
LBRX Q1 2026 Earnings: EPS Beat Estimates as Biotech Advances PipelineEarnings Quality Score - newsline.com
LB Pharmaceuticals (LBRX) grants director 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) awards 10,000 options to director vesting in 2027 - Stock Titan
[Form 4] LB PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
LB Pharmaceuticals (LBRX) director receives 12,500 stock options at $27.95 strike - Stock Titan
LB Pharmaceuticals (LBRX) director receives 10,000 stock options at $27.95 strike - Stock Titan
Director at LB Pharmaceuticals (LBRX) receives grant of 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) director awarded 10,000 stock options at $27.95 - Stock Titan
LBRX: All proposals passed, electing directors and ratifying the auditor for 2026 - TradingView
LB Pharmaceuticals Inc (LBRX) Q1 2026 Earnings: EPS Surprise on Lower-Than-Expected LossOperating Income Trends - newsline.com
LB Pharmaceuticals (LBRX) Q1 2026 Earnings: EPS Surprise Signals Improving Operational DisciplineBook Value Growth - newsline.com
LBRX News Today | Why did LB Pharmaceuticals stock go up today? - MarketBeat
Schizophrenia drug developer LB Pharmaceuticals heads to June investor talks - Stock Titan
LBRX Options Chain — NASDAQ:LBRX - TradingView
Top LB Pharmaceuticals (LBRX) Competitors 2026 - MarketBeat
Bipolar Depression Market Poised for Robust Growth with Upcoming Novel Therapies and Improved Diagnostics - Barchart.com
All you need to know about LB Pharmaceuticals Inc (LBRX) rating upgrade to buy - MSN
Clear Street initiates LB Pharmaceuticals stock with buy rating - Investing.com
Clear Street initiates LB Pharmaceuticals stock with buy rating By Investing.com - Investing.com South Africa
LB Pharmaceuticals Inc (LBRX) Edges Higher Amid Sector Strength – Key Levels in FocusPoint of Control - The Legal Advocate
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target - Investing.com UK
LB Pharmaceuticals: Buy Rating Reiterated, $45 Price Target Maintained on LB-102 Late-Stage Pipeline and Multi-Billion-Dollar Sales Potential - TipRanks
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy - Yahoo Finance
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock, $45 target By Investing.com - Investing.com Australia
LB Pharmaceuticals (LBRX) Edges Higher as Trading Activity Remains SteadyMACD Signal Stocks - newsline.com
LB Pharmaceuticals (LBRX) Holds Near Resistance as Modest Gain Signals ConsolidationHigh Volume Node - The Legal Advocate
LB Pharmaceuticals Inc (LBRX) Holds Steady Near Resistance as Market Watches for BreakoutCovered Call Trade - Newser
LB Pharmaceuticals Inc (LBRX) Breaks Higher as Volume Picks Up; Key Resistance AheadRetail Trader Picks - Newser
Why Is LB Pharmaceuticals Inc Common Stock (LBRX) Stock Down Today? - Meyka
LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans - Sahm
Number of shareholders of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
TCG Crossover entities report 1.84M shares in LB Pharmaceuticals (LBRX) - Stock Titan
Commodore Capital (LBRX) files Schedule 13G/A reporting 1.97M shares - Stock Titan
Caligan Partners discloses 1.44M shares in LB Pharmaceuticals (LBRX) - Stock Titan
Craig-Hallum Keeps Their Buy Rating on LB Pharmaceuticals, Inc. (LBRX) - The Globe and Mail
JPMorgan (NYSE: JPM) files amendment showing 1.43M LBRX shares (4.9%) - Stock Titan
This LB Pharmaceuticals analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN
LBRX: LB-102 demonstrates rapid efficacy and strong safety in late-stage trials for major neuropsychiatric disorders - TradingView
LB Pharmaceuticals (LBRX) reports $365.6M cash, Q1 net loss $19.1M - Stock Titan
LB Pharmaceuticals (NASDAQ: LBRX) boosts cash for late-stage LB-102 trials - Stock Titan
Lb Pharmaceuticals Inc (LBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lb Pharmaceuticals Inc 주식 (LBRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
2,000,000 |
30,000,000 |
2,686,138 |
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
666,666 |
9,999,990 |
666,666 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Nussbaum Ran | Director |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Vida Ventures GP III, L.L.C. | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
333,333 |
4,999,995 |
880,214 |
2.60%
0.94%
자본화:
|
볼륨(24시간):